Cited by 522Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

Open access

Scharping, Nicole E., Menk, Ashley V., Whetstone, Ryan D., Zeng, Xue, Delgoffe, Greg M.·2017·Cancer Immunology Research

DOI 10.1158/2326-6066.cir-16-0103PMC PMC5340074

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Blockade of the coinhibitory checkpoint molecule PD-1 has emerged as an effective treatment for many cancers, resulting in remarkable responses. However, despite successes in the clinic, most patients do not respond to PD-1 blockade. Metabolic dysregulation is a common phenotype in cancer, but both patients and tumors are metabolically heterogeneous. We hypothesized that the deregulated oxidative energetics of tumor cells present a metabolic barrier to antitumor immunity through the generation of a hypoxic microenvironment and that normalization of tumor hypoxia might improve response to immunotherapy. We show that the murine tumor lines B16 and MC38 differed in their ability to consume oxygen and produce hypoxic environments, which correlated with their sensitivity to checkpoint blockade. Metformin, a broadly prescribed type II diabetes treatment, inhibited oxygen consumption in tumor cells in vitro and in vivo, resulting in reduced intratumoral hypoxia. Although metformin monotherapy had little therapeutic benefit in highly aggressive tumors, combination of metformin with PD-1 blockade resulted in improved intratumoral T-cell function and tumor clearance. Our data suggest tumor hypoxia acts as a barrier to immunotherapy and that remodeling the hypoxic tumor microenvironment has potential to convert patients resistant to immunotherapy into those that receive clinical benefit. Cancer Immunol Res; 5(1); 9–16. ©2016 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0103

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 7×
“org Cancer Immunol Res; 5(1) January 2017 11”
BackgroundInfluential
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · cited 2×
“can be metabolically plastic, and are primed to utilize glucose in oxygen-poor conditions, glucose, too, can be limiting in the tumor microenvironment (15,16).”
Background
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“It is established that patients taking metformin for type II diabetes have a decreased risk of cancer (17, 18) and that much of the antitumor metformin effect can be attributed to T cells (19).”
Background
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462 · cited 2×
“However, in the tumor microenvironment, as glucose is limiting, only cells able to effectively compete for glucose would experience an enhanced response (15, 16).”
Background
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848
Self-citation
Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism
Peng, M., Yin, N., Chhangawala, S., Xu, K., Leslie, C. S., & Li, M. O. (2016) · Science · doi:10.1126/science.aaf6284 · Cited by 787 · cited 1×
“to effector function epigenetically and post-transcriptionally (26-28).”
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 708 · cited 1×
“We have previously shown that T cells in the tumor microenvironment are at a metabolic disadvantage and repress oxidative metabolism (13).”
BackgroundSelf-citation

Show all 30 references

Sorted by citations

Items 301–400 of 522

Metabolic rewiring directs melanoma immunology
Sun, N., Tian, Y., Chen, Y., Guo, W., & Li, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909580 · Cited by 19
“Then the combination of metformin and antiPD-1 antibody is found to improve intra-tumoral T-cell function in a preclinical mouse model (157).”
Background
Comedications with Immune Checkpoint Inhibitors: Involvement of the Microbiota, Impact on Efficacy and Practical Implications
Colard‐Thomas, J., Thomas, Q. D., & Viala, M. (2023) · Cancers · doi:10.3390/cancers15082276 · Cited by 18
“That barrier to immunotherapy could be reduced by metformin-induced diminution of oxygen consumption in tumor cells, allowing for higher infiltration by T cells and better tumor response [102].”
Background
Commensal bacterial hybrid nanovesicles improve immune checkpoint therapy in pancreatic cancer through immune and metabolic reprogramming
Liu, G., Huang, W., Chen, L., Tayier, N., You, L., Hamza, M., Tian, X., Wang, H., Nie, G., Zhu, M., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101993 · Cited by 17
Immunometabolism: a new dimension in immunotherapy resistance
Xiao, C., Xiong, W., Xu, Y., Zou, J. P., Zeng, Y., Liu, J., Peng, Y., Hu, C., & Wu, F. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1012-z · Cited by 18
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors
Scherwitzl, I., Opp, S., Hurtado, A. M., Pampeno, C., Loomis, C. A., Kannan, K. S., Yu, M., & Meruelo, D. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.012 · Cited by 19
“T cell metabolic output was measured by Seahorse technology as previously described.(94) Purified T cells were plated at 6 10(5) cells/well in an Agilent Seahorse XF24 cell culture microplate.”
Method
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
Spitschak, A., Gupta, S. K., Singh, K. P., Logotheti, S., & Pützer, B. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010083 · Cited by 17
Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective
Yang, H., Wu, C.-Y., Powell, J. D., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114030 · Cited by 17
“Similarly, metabolic interventions can also be directed against tumor cells, as inhibiting tumor glycolysis also improves T cell-mediated anti-tumor effects both in vitro and in vivo [216], while another study has shown that the efficacy of ICI therapy was promoted by the inhibitory effect of metformin on oxygen consu…”
Background
Local Destruction of Tumors and Systemic Immune Effects
Tranberg, K. ‐. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708810 · Cited by 17
The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy
Akter, Z., Salamat, N., Ali, M. Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072739 · Cited by 17
Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy
Feng, X., Chen, Z., Liu, Z., Fu, X., Song, H., & Zhang, Q. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122970 · Cited by 16
Advances in the Use of Metformin for Liver Disease
Bao, J., Zhao, Y., Xu, X., & Ling, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673274268231215110330 · Cited by 16
Turning Fluvastatin into a supramolecular immuno-sensitizer towards augmented tumor immunotherapy
Ma, F., Liu, T., Yang, W., You, W., He, W., Yan, J., & Liu, W. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.135310 · Cited by 15
Intranasal Delivery of Recombinant S100A8 Protein Delays Lung Cancer Growth by Remodeling the Lung Immune Microenvironment
Wong, S. W., McCarroll, J. A., Hsu, K., Geczy, C. L., & Tedla, N. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826391 · Cited by 15
“(77) reported that administration of the mitochondrial complex 1 inhibitor, Metformin, reduced intratumoral hypoxia and increased the efficacy of a PD-1 inhibitor to enhance intratumoral T cell function and cancer clearance in aggressive cancer mouse models.”
Background
Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment
Wang, P., Wang, X., Man, C., Gong, D., & Fan, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200619 · Cited by 17
Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin
Smith, R. J., Zollo, R. A., Kalvapudi, S., Vedire, Y., Pachimatla, A. G., Petrucci, C. M., Shaller, G., Washington, D., Vethanayagam, R. R., Sass, S. N., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae295 · Cited by 15
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review)
Han, P., Zhou, J., Xiang, J., Liu, Q., & Sun, K. (2022) · Oncology Reports · doi:10.3892/or.2022.8440 · Cited by 16
“Metformin increases oxygen supply to TILs, rescues T cells from an anoxic environment and enhances their role, and may have potential for the immune treatment of patients (90).”
Background
Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies
Faraj, J. A., Al-Athari, A. J. H., Mohie, S. E. D., Kadhim, I. K., Jawad, N. M., Abbas, W. J., & Jalil, A. T. (2022) · Medical Oncology · doi:10.1007/s12032-022-01842-5 · Cited by 16
“els in TME, thus, improving T cell response to anti-PD1 immunotherapy [111].”
Background
Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer
Wang, L., Izadmehr, S., Sfakianos, J. P., Tran, M. A., Beaumont, K. G., Brody, R., Cordon‐Cardo, C., Horowitz, A., Sebra, R., Oh, W. K., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109928 · Cited by 15
Mitochondrial bioenergetics and networks in melanoma: an update
Giannitti, G., Paganoni, A. J. J., Marchesi, S., Garavaglia, R., & Fontana, F. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02155-4 · Cited by 15
Exploration of Fully‐Automated Body Composition Analysis Using Routine CT‐Staging of Lung Cancer Patients for Survival Prognosis
Künnemann, M., Römer, C., Helfen, A., Bleckmann, A., Kemper, M., Heindel, W. L., Brix, T. J., Forsting, M., Haubold, J., Opitz, M. K., et al. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70021 · Cited by 14
“Metformin, studied for its anticancer and immunomodulatory effects, shows variable potency in preclinical and clinical studies [35] [S7].”
Mitochondrial transfer at the crossroads of cancer, stromal, and immune cells
Ishino, T., Inutsuka, Y., Ikeda, H., & Togashi, Y. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.10.004 · Cited by 17
Programmed cell death‐1 blockade therapy in melanoma: Resistance mechanisms and combination strategies
Zou, Y., & Yaguchi, T. (2023) · Experimental Dermatology · doi:10.1111/exd.14750 · Cited by 14
Repurposing Metformin in hematologic tumor: State of art
Hu, M., Chen, Y., Ma, T., & Li, J. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100972 · Cited by 15
Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors
Shen, J., Ye, X., Hou, H. Y., & Wang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112243 · Cited by 15
CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production
García‐Cañaveras, J. C., Heo, D. S., Trefely, S., Leferovich, J. M., Xu, C. B., Philipson, B. I., Ghassemi, S., Milone, M. C., Moon, E. K., Snyder, N. W., et al. (2021) · Cells · doi:10.3390/cells10092334 · Cited by 15
“Intra-tumoral hypoxia correlates with T-cell hypofunction and poor response to PD-1 blockade in syngeneic models of melanoma [7].”
Background
Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
Lemon, L. S., Orr, B. C., Modugno, F., Buckanovich, R. J., Coffman, L. G., Edwards, R. P., & Taylor, S. E. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.022 · Cited by 16
Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies
He, Y., Gong, F., Jin, T., Liu, Q., Fang, H., Chen, Y., Wang, G., Chu, P. K.-H., Wu, Z., & Ostrikov, K. (2023) · Biomolecules · doi:10.3390/biom13040707 · Cited by 14
“In addition, tumor cells treated with metformin to decrease mitochondrial ROS/RNS levels exhibit activation of tumor T cells and enhanced therapeutic effects of the PD-1 blockade [63,64].”
Background
Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
To, K. K. W., & Cho, W. C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082166 · Cited by 16
Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity
Zhang, S., Zhang, X., Yang, H., Liang, T., & Bai, X. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189022 · Cited by 14
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration
Liu, A. J., Gammon, S. T., Pisaneschi, F., Boda, A. R., Ager, C. R., Piwnica-Worms, D. R., Hong, D. S., & Curran, M. A. (2023) · JCI Insight · doi:10.1172/jci.insight.169150 · Cited by 15
“These phenotypic changes in CD8 + T cells are consistent with previous reports demonstrating that reversal of hypoxia and normalization of tumor vasculature improve antitumor CD8 + T cell function (7, 9, 23–26).”
CD8 + and FoxP3 + T‐Cell Cellular Density and Spatial Distribution After Programmed Death‐Ligand 1 Check Point Inhibition
Curry, J., Alnemri, A. E., Philips, R. H. W., Fiorella, M. A., Sussman, S. M., Stapp, R., Solomides, C., Harshyne, L. A., South, A. P., Luginbuhl, A., et al. (2022) · The Laryngoscope · doi:10.1002/lary.30389 · Cited by 13
“Given the evidence for benefit of metformin in HNSCC, investigators have studied the potential benefit of adding metformin to immune checkpoint inhibitors in animal models with encouraging results.(46) In this study, posttreatment analysis revealed a significant decrease in FoxP3+ CD and increase in CD8+ CD in the TAS…”
Result
Metformin enhances T lymphocyte anti-tumor immunity by increasing the infiltration via vessel normalization
Li, G., Feng, Y.-Q., Jia, Y., Wang, K.-F., Li, Y., Zhang, S., Han, S., & Wang, J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175592 · Cited by 13
Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade
Chew, G. M., Padua, A. J., Chow, D. C., Souza, S. A., Clements, D. M., Corley, M. J., Pang, A. P. S., Alejandria, M. M., Gerschenson, M., Shikuma, C. M., et al. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0172 · Cited by 13
“Metformin potentiated the effects of PD-1 blockade on antitumor T cells by remodeling the hypoxic tumor microenvironment.(13) Moreover, metformin combined with anti-PD-1 and anti-CTLA-4 was shown to have favorable treatmentrelated outcomes in metastatic malignant melanoma patients.”
Background
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
Weppler, A. M., Pattison, A., Bhave, P., Ieso, P. B. D., Raleigh, J., Hatzimihalis, A., Gill, A. J., Balachander, S., Callahan, J., Chua, M. S.-T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000700 · Cited by 13
ERADicate Tumor Progression with Metformin
Dreher, L.-S., & Hoppe, T. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.08.001 · Cited by 12
The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy
Hussein, O., Rayan, M., Matarid, T. R., Elkhalifa, D. H., Abunada, H. H., Therachiyil, L., Khalil, A. A., Shahab Uddin, M. S., Maccalli, C., & Korashy, H. M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03514-4 · Cited by 14
“…transition factor (c-MET) has been implicated in promoting tumor progression, metastasis and angiogenesis, whereas its Melanoma and CRC Anti-PD-1 Metformin Improved anti-tumor activity and enhanced T cell activity [332] inhibition has shown survival benefits in a phase II clinical trial [71, 357].”
The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors
Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 13
“Improved tumour control was particularly apparent in the ICI-resistant B16 melanoma model with B16 melanoma cells shown to have a higher rate of oxygen consumption than MC38 tumour cells in vitro 190 .”
Influential
Influences of preoperative metformin on immunological factors in early breast cancer
Tsukioki, T., Shien, T., Tanaka, T., Suzuki, Y., Kajihara, Y., Hatono, M., Kawada, K., Kochi, M., Iwamoto, T., Ikeda, H., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04092-2 · Cited by 12
Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective
Liu, N., Shan, F., & Ma, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108017 · Cited by 13
Metformin-induced reduction of CCR8 enhances the anti-tumor immune response of PD-1 immunotherapy in glioblastoma
Li, Y., Liu, B., Cao, Y., Cai, L., Zhou, Y., Yang, W., & Sun, T. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176274 · Cited by 12
Metformin in Colorectal Cancer: Epidemiological Evidence, Predictive Biomarkers, and Implications for Prevention and Treatment
Myung, S., Park, Y. Y., & Kim, M. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136040 · Cited by 12
“This could help prevent the TME from becoming immunosuppressive and boost the effects of the immune checkpoint blockade [49,53].”
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine RestrictionPreprint
Morehead, L. C., Garg, S., Wallis, K., Siegel, E. R., Tackett, A. J., & Miousse, I. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.05.535695 · Cited by 12
“to immune checkpoint inhibitors in animal models (42).”
Background
A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes
Pedrosa, L., Foguet, C., Oliveres, H., Archilla, I., de Herreros, M. G., Rodríguez, A., Postigo, A. A., Benítez‐Ribas, D., Camps, J., Cuatrecasas, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926304 · Cited by 11
“We hypothesize that autophagy inhibitors such as chloroquine (27) or selective autophagy target inhibitors (38) such as metformin (a citrate transport and gluconeogenesis inhibitor) (39, 40), or CCS1477 (an inhibitor of p300/CBP) currently in clinical development (41, 42), can increase ICI efficacy in this cluster.”
Background
Microneedles‐Mediated Intradermal Delivery of Paclitaxel/Anti‐PD‐1 for Efficient and Safe Triple‐Negative Breast Cancer Therapy
Wang, J., Wen, T., Chen, H., Huang, S., Guo, R., Zheng, Y., Xiao, Z., & Shuai, X. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300362 · Cited by 11
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments
Santamaria, F., Roberto, M., Buccilli, D., Civita, M. A. D., Giancontieri, P., Maltese, G., Nicolella, F., Torchia, A., Scagnoli, S., Pisegna, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104405 · Cited by 11
Inhibition of OXPHOS induces metabolic rewiring and reduces hypoxia in murine tumor models
Boreel, D. F., Beerkens, A. P. M., Heskamp, S., Boswinkel, M., Peters, J. P. W., Adema, G. J., Span, P. N., & Bussink, J. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100875 · Cited by 11
“[ 18 F]FDG uptake assay [ 18 F]fluorodeoxyglucose (FDG) (150 kBq/well) (Radboud Trans-lational Medicine) was added to medium of cells cultured to confluency in 6-well plates (Corning) or spheroids cultured in 96-well plates, followed by incubation for 2 h at 37 ◦ C and 5.0 % CO 2 .”
BackgroundMethodResultInfluential
Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity
Chen, J., Wang, S., Ding, Y., Duo, X., & Zheng, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1568634 · Cited by 13
Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma
You, J., Yang, X., Zhao, J., Chen, H., Tang, Y., Ouyang, D., Liu, Y., Wang, Y., Xie, S., Chen, Y., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.110406 · Cited by 13
Metabolic hallmarks of type 2 diabetes compromise T cell function
Liang, Y., Chen, W., Gao, Q., Tan, K. C. B., Lee, C., & Ling, G. S. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.08.005 · Cited by 11
Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
Zou, R., Wang, Y., Ye, F., Zhang, X., Wang, M., & Cui, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02637-2 · Cited by 11
The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer
Kaczmarek, K., Wieckiewicz, J., Węglarczyk, K., Siedlar, M., & Baran, J. (2021) · Cancers · doi:10.3390/cancers13123004 · Cited by 11
Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers in vitro
Repas, J., Peternel, L., Sourij, H., & Pavlin, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216193 · Cited by 12
Metformin Prevents Peritoneal Dissemination via Immune-suppressive Cells in the Tumor Microenvironment
Hirayama, T., Nagata, Y., Nishida, M., Matsuo, M., Kobayashi, S., Yoneda, A., Kanetaka, K., Udono, H., & Eguchi, S. (2019) · Anticancer Research · doi:10.21873/anticanres.13652 · Cited by 11
Cutting-Edge CAR Engineering: Beyond T Cells
Chocarro, L., Blanco, E., Fernández, L., Arasanz, H., Bocanegra, A., Echaide, M., Garnica, M., Ramos, P., Piñeiro‐Hermida, S., Vera, R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10123035 · Cited by 11
Potent and Targeted Sindbis Virus Platform for Immunotherapy of Ovarian Cancer
Opp, S., Hurtado, A. M., Pampeno, C. L., Lin, Z., & Meruelo, D. (2022) · Cells · doi:10.3390/cells12010077 · Cited by 11
Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
Mudassar, F., Shen, H. M., Cook, K. M., & Hau, E. K. C. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13416 · Cited by 10
“In another study, metformin-induced reduction in tumour hypoxia enhanced the effect of PD-1 blockade immunotherapy by improving the function of cytotoxic T cells.(148) Another compound, atovaquone, an anti-malarial drug and a mitochondrial complex III inhibitor, was found to reduce the OCR in numerous cancer cell line…”
Background
T cells in the peritoneum
Rathod, S. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.013 · Cited by 10
Nanodelivery Systems Delivering Hypoxia-Inducible Factor-1 Alpha Short Interfering RNA and Antisense Oligonucleotide for Cancer Treatment
Yan, Y., Li, H., Yao, H., & Cheng, X. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.932976 · Cited by 10
Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models
Boreel, D. F., Span, P. N., Kip, A., Boswinkel, M., Peters, J. P. W., Adema, G. J., Bussink, J., & Heskamp, S. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00045 · Cited by 11
Genome-Wide Analysis Reveals Hypoxic Microenvironment Is Associated With Immunosuppression in Poor Survival of Stage II/III Colorectal Cancer Patients
Chen, Y., Yu, Z., Lv, M., Zheng, B., Tan, Y., Ke, J., Liu, X., Cai, Z., Zou, Y., Lan, P., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.686885 · Cited by 10
“As hypoxic microenvironment could provide tumor resistant to immunotherapy (42, 43), which has emerged as an effective therapy for CRC (44, 45), HRGS may have the potential to predict the outcome of the immunotherapy.”
Background
Highly active selenium nanotherapeutics combined with metformin to achieve synergistic sensitizing effect on NK cells for osteosarcoma therapy
Du, Y., Zhang, Z., Yang, Y. S., Liu, T., Chen, T., & Li, X. (2022) · Nanophotonics · doi:10.1515/nanoph-2022-0289 · Cited by 10
Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer
Zheng, Z., Bian, C., Wang, H., Su, J., Meng, L., Xin, Y., & Jiang, X. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138383 · Cited by 10
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS
Gobbini, É., Langlais, A., Missy, P., Chanoine, S., Besse, B., Souquet, P.-J., Barlési, F., Audigier-Valette, C., Métivier, A.-C., Monnet, I., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115560 · Cited by 10
Mitochondria-targeted strategies in tumor immunity
Cheng, X., Wang, Y., Johnson, B., & You, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646138 · Cited by 10
SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma
Jiang, A., Liu, Y., Zhu, B., Fang, Y., Qu, L., Yang, Q., Luo, P., Cai, C., & Wang, L. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.01.005 · Cited by 9
Longitudinal monitoring of tumor response to immune checkpoint inhibitors using noninvasive diffuse reflectance spectroscopy
Troncoso, J. R., Díaz, P. M., Lee, D. E., Quick, C. M., & Rajaram, N. (2021) · Biomedical Optics Express · doi:10.1364/boe.426879 · Cited by 9
Clinical Implication of Metformin in Relation to Diabetes Mellitus and Ovarian Cancer
Singh, S. K., Apata, T., Singh, S., McFadden, M., & Singh, R. (2021) · Biomedicines · doi:10.3390/biomedicines9081020 · Cited by 9
“In a separate survey, metformin enhances the efficacy of PD-1 blockade by reducing the tumor hypoxia in a mouse model [66].”
Background
Oxygen therapy in traditional and immunotherapeutic treatment protocols of cancer patients: current reality and future prospects
Seledtsov, V. I., & von Delwig, A. A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2070153 · Cited by 9
“Another study showed a correlation between the ability of mouse tumor cell lines to consume oxygen with their sensitivity to PD-1 checkpoint blockade [46], thus sug-”
Background
Orthotopic and heterotopic triple negative breast cancer preclinical murine models: A tumor microenvironment comparative
Santana-Krímskaya, S. E., Kawas, J. R., Zárate-Triviño, D. G., Ramos-Zayas, Y., Rodrı́guez-Padilla, C., & Franco-Molina, M. Á. (2022) · Research in Veterinary Science · doi:10.1016/j.rvsc.2022.08.026 · Cited by 10
A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy
Jiang, A., Song, J., Fang, X., Fang, Y., Wang, Z., Liu, B., Wu, Z., Qu, L., Luo, P., & Wang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1029509 · Cited by 9
CRISPR/Cas9-mediated SHP-1-knockout T cells combined with simvastatin enhances anti-tumor activity in humanized-PDX HCC model
Liu, H., Ge, W., Yu, X., Luo, J., Zhang, J., Yang, M., Cao, L., Zhang, Y., Wang, R., Yang, C., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112266 · Cited by 8
“22,23 Moreover, contrary to the long-held view that tumors are mostly glycolytic, oxidative phosphorylation active in many malignancies, representing a possible therapeutic target.”
Multi-omics unveils BCAA metabolism markers L-leucine and HMGCS1 as prognostic marker for immunotherapy efficacy in non-small cell lung cancer
Dai, L., Wang, X., Lou, N., Li, L., Huang, L., Tang, L. M., Yao, J., Shi, Y., & Han, X. (2025) · Respiratory Research · doi:10.1186/s12931-025-03277-8 · Cited by 8
“Combining metformin with PD-1 inhibitors enhances the anti-tumor efficacy of PD-1 inhibitors [59, 61, 62].”
Metabolic modulation of CD8⁺ T cells by metformin: A promising adjuvant strategy for CD8⁺ T Cell-Based Immunotherapies
Ton, N. Q. C., & Park, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108015 · Cited by 10
Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma
Howell, A. V., Gebregziabher, M., THIERS, B. H., Paulos, C. M., Wrangle, J. M., Hunt, K. J., & Wallace, K. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.09.023 · Cited by 9
Rewired Cellular Metabolic Profiles in Response to Metformin under Different Oxygen and Nutrient Conditions
Liu, S., Washio, J., Sato, S., Abiko, Y., Shinohara, Y., Kobayashi, Y., Otani, H., Sasaki, S., Wang, X., & Takahashi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020989 · Cited by 8
Redox Signaling Modulates Activity of Immune Checkpoint Inhibitors in Cancer Patients
Allegra, A., Murdaca, G., Mirabile, G., & Gangemi, S. (2023) · Biomedicines · doi:10.3390/biomedicines11051325 · Cited by 8
“Additionally, this would diminish intratumoural hypoxia [53].”
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies
Augustin, R. C., Cai, W. L., Luke, J. J., & Bao, R. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2241 · Cited by 7
Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies
Alanazi, F. E., Sobeai, H. M. A., Alhazzani, K., Al‐Dhfyan, A., Alshammari, M. A., Alotaibi, M. R., Alhosaini, K. A., Korashy, H. M., & Alhoshani, A. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.12.014 · Cited by 8
A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma
Jiang, A., Wu, X., Wang, D., Wang, A., Dong, K., Liu, B., Qu, L., Luo, P., Wang, J., Tong, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935595 · Cited by 8
“Hypoxic stress was an important feature of tumor metabolism and prompted resistance to immunotherapy in cancers (24, 25).”
Background
Immune Cell Metabolism and Immuno-Oncology
Patel, C. H., & Powell, J. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-042605 · Cited by 9
Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors
Fatima, Z., Abonofal, A., & Stephen, B. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-27 · Cited by 9
“Metformin was shown to decrease hypoxia in the TME by reducing the expression of HIF-1 and angiogenesis-associated factors and thus potentiate the anticancer effect of programmed cell death protein 1 (PD-1) inhibitors.([69]) Immune exhaustion is a common phenomenon after treatment with ICI.”
Background
Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application
Oh, T., Kim, M.-W., Kang, G.-S., Ye, S., Choi, C., Park, W., Hay, M. P., Hirata, H., & Ahn, G. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.200 · Cited by 7
“Interestingly, in that study metformin alone has also shown to increase the number of PD-1+ and Tim-3+ exhausted T cells in tumors [88] and this might have counter affected the cytotoxic activities of CD44 hi activated T cells in exerting the tumor control.”
Influential
Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
Llerena, P., Samarah, H., Nunes, K. L., Lin, Z., Bridgham, K., Tekumalla, S., Jain, A., Harshyne, L. A., Shukla, S. K., Vathiotis, I. A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1098 · Cited by 8
“These effects are accompanied by restoration of oxidative metabolism and reinvigora-tion of exhausted CD8 + T cells, ultimately enhancing the efficacy of PD-1 blockade in vivo (26).”
Beyond diabetes: harnessing the power of metformin in burn care
Khalaf, F., Touma, D., Saldanha, S., Khalaf, G., Barayan, D., & Jeschke, M. G. (2025) · Critical Care · doi:10.1186/s13054-025-05662-7 · Cited by 9
“Metformin’s effects are context-dependent: it enhances immune activity in tumors [166–168] but is predominantly anti-inflammatory in tuberculosis and multiple sclerosis [169–175], reflecting its capacity to fine-tune immune responses according to environmental cues.”
The Role of Hypoxia in Brain Tumor Immune Responses
Park, J. H., & Lee, H. K. (2023) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2022.0043 · Cited by 8
“have been observed in hypoxic CD8 T cell cultures [77] and”
Background
Challenges and opportunities for cancer stem cell‐targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell‐dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes
Alqarni, A., Jasim, S. A., Altalbawy, F. M. A., Kaur, H., Kaur, I., Rodriguez‐Benites, C., Deorari, M., Alwaily, E. R., Al‐Ani, A. M., & Redhee, A. H. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23719 · Cited by 8
Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation
Wang, Y., Hu, J., Sun, Y. L., Song, B., Zhang, Y., Lu, Y., & Ma, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5983959 · Cited by 7
“-e cytokines TNF-α, IL-2, and IFN-c secretion in CD8+ Tcells was significantly increased, and the immune response was enhanced by metformin synergized with PD-L1 MAb.”
BackgroundInfluential
Retracted
Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?
Dhawan, A., Pifer, P. M., Sandulache, V. C., & Skinner, H. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016217 · Cited by 8
“Furthermore, given that hypoxia in the TME acts as a barrier to immunotherapy, a recent study determined that metformin led to reduction of tumor hypoxia which improved the efficacy of PD-1 blockade and could reduce immunotherapy resistance (133).”
Background
Application of radiomics in lung immuno‐oncology
Yan, W., Chen, Q., Mourad, W. F., Yuan, J. D., Shi, Z., Yang, J., Lu, Q., & Zhang, J. (2023) · Precision Radiation Oncology · doi:10.1002/pro6.1191 · Cited by 8
The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Nguyen, N. N., Nguyen, T. H. H., Hoang, K. D., Vo, T., Pham, Q. H. M., & Chen, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111930 · Cited by 6
Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors
Zhou, M., Xu, L., Hu, J., Chen, W., Hong, J., Wang, M.-H., & Guo, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07278-5 · Cited by 9
“Scharping et al. found that metformin could mitigate the hypoxic level within solid tumors and improve the efficacy of PD-1 blockade [50], while Finisguerra et al. showed that metformin facilitated adoptive cell therapy (ACT) through increasing the infiltration of T cells in hypoxic tumor tissues,…”
Metformin’s multifaceted role in colorectal cancer: mechanisms of action and synergy with standard treatments
Kolour, H. R., Bahrami, N., Mojarad, E. N., Sadeghi, A., Shamsara, M., & Fatemi, N. (2025) · Discover Oncology · doi:10.1007/s12672-025-03905-1 · Cited by 6
“For instance, Scharping et al. (2017) showed that metformin can reduce tumor hypoxia and modulate the tumor microenvironment, thereby enhancing the efficacy of PD-1 blockade [142, 143].”
The glycolysis-lactylation axis: a metabolic-epigenetic driver of immunosuppression and therapy resistance in cancer
Tan, S., Zhang, W., Ding, Y., Liu, J., Zhu, M., Luo, X., Cai, J., & Zeng, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772701 · Cited by 9
“Furthermore, the close association of lactylation with the PD-1/PD-L1 axis, tumor angiogenesis, and chemotherapy resistance positions it as an ideal molecular target for combination strategies integrating metabolic interventions such as LDH inhibitors with immunotherapy (51, 52).”
Targeting T cell metabolism for immunotherapy
Gao, J., Liu, Y., Wei, J., Jiang, L., Mao, J., Chang, C.-H., & Wu, D. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0921-011r · Cited by 6
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma
Morehead, L. C., Koss, B. S., Fil, D., Heflin, B., Garg, S., Wallis, K., Tackett, A. J., & Miousse, I. R. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.10.003 · Cited by 7
Transcriptomic analysis reveals oxidative stress-related signature and molecular subtypes in cholangio carcinoma
Wu, Z. (2024) · Molecular Genetics and Genomics · doi:10.1007/s00438-024-02170-1 · Cited by 6
“Dysregulated oxidative stress signaling can modulate immune cell function, cytokine production, and immune checkpoint expression, thereby shaping the tumor immune microenvironment (Cheng et al. 2016; Scharping et al. 2017).”
Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer
Zschaeck, S., Zöphel, K., Seidlitz, A., Zips, D., Kotzerke, J., Baumann, M. A., Troost, E. G. C., Löck, S., & Krause, M. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.030 · Cited by 6
Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
Kang, S., Khalil, L. E., McCook‐Veal, A. A., Liu, Y., Galvin, J., Draper, A., Kokabi, N., Diab, M., Shaib, W. L., Alese, O. B., et al. (2023) · Liver Cancer International · doi:10.1002/lci2.71 · Cited by 7
O-GlcNAcylation at the center of antitumor immunity
Heieis, G. A., & Everts, B. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103009 · Cited by 6

Authors: Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M.
Affiliations: University of Pittsburgh (US)
UPMC Hillman Cancer Center (US)
Corresponding author: Delgoffe, Greg M.
ORCID: Scharping, Nicole E.
Menk, Ashley V.
Zeng, Xue
Delgoffe, Greg M.
Venue: Cancer Immunology Research
Publisher: American Association for Cancer Research (AACR)
Published: 2017-01-01
Volume: 5
Issue: 1
Pages: 9-16
ISSN: 2326-6066 (ISSN-L)
2326-6074
DOI: 10.1158/2326-6066.cir-16-0103
PMC: PMC5340074
OpenAlex: W2560185130
Cited by: 520
References: 30
Citations by year: 2026: 34 · 2025: 53 · 2024: 49 · 2023: 72 · 2022: 85 · 2021: 79 · 2020: 69 · 2019: 38 · 2018: 30 · 2017: 11
FWCI: 14.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Immunology Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: UPCI (P30CA047904)
Sidney Kimmel Foundation for Cancer Research (SKF-015-039)
University of Pittsburgh Cancer Institute Skin Cancer (P50CA121973-08)
University of Pittsburgh Cancer Institute Head and Neck Cancer SPORE (P50 CA097190)
Cancer-AACR Innovative Research (SU2C-AACR-IRG-04-16)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: anti-PD-1 therapy, metformin, tumor hypoxia, tumor microenvironment, cancer immunotherapy resistance, combination therapy, oxidative metabolism, T cell function, B16 melanoma, MC38 colon carcinoma, antitumor immunity
MeSH terms: Tumor Hypoxia, Antineoplastic Agents, Immunological, Animals, Cytotoxicity, Immunologic, Drug Synergism, Energy Metabolism, Melanoma, Experimental, Metformin, Oxygen Consumption, T-Lymphocytes, Cytokines, Lymphocytes, Tumor-Infiltrating, Mice, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks